title: Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.
abstract: Oxaliplatin-based chemotherapy for colorectal cancer demonstrates interindividual variability in response, and polymorphisms of ERCC1, ERCC2, XRCC1, GSTP1 and GSTM1 genes may be contributing factors. Additionally, the effect of these genotypes may differ between ethnic groups. Material & Methods: A meta-analysis of the association between these genotypes and response, progression-free survival and overall survival (OS) for patients with colorectal cancer treated with oxaliplatin-based therapy is reported. Results: ERCC1 C118T (TT vs CC OS [hazard ratio (HR): 2.59; p = 0.001]), ERCC2 A2251C (CC or AC vs AA OS [HR: 1.53; p = 0.04]) and GSTP1 A313G (GG vs AA OS, [HR: 0.47; p < 0.001]) polymorphisms were associated with survival. The effect size may be larger for ERCC1 C118T and XRCC1 G1196A in Asian compared with Caucasian populations. No association was apparent for the GSTM1 genotype.
  
  
  
  ERCC1 C118T, ERCC2 A2251C and GSTP1 A313G polymorphisms were associated with clinical outcomes.
authors.affiliation: Medical School, The Australian National University, Building 4, The Canberra Hospital Road, Garran, Canberra, Australia 2605.
authors.forename: Adel
authors.initials: A
authors.lastname: Shahnam
authors.affiliation: Medical School, The Australian National University, Building 4, The Canberra Hospital Road, Garran, Canberra, Australia 2605.
authors.forename: Zainab
authors.initials: Z
authors.lastname: Ridha
authors.affiliation: School of Pharmacy & Medical Sciences, University of South Australia, Adelaide, Australia.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Wiese
authors.affiliation: Flinders Centre for Innovation in Cancer, School of Medicine, Flinders University, Adelaide, Australia.
authors.forename: Ganessan
authors.initials: G
authors.lastname: Kichenadasse
authors.affiliation: Department of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide, Australia.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Sorich
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000208:ethnology / Q000235:genetics / Q000401:mortality; D004268:DNA-Binding Proteins / Q000235:genetics; D004720:Endonucleases / Q000235:genetics; D051549:Glutathione S-Transferase pi / Q000235:genetics; D005982:Glutathione Transferase / Q000235:genetics; D006801:Humans; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D000077150:Oxaliplatin; D010597:Pharmacogenetics; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D004720:Endonucleases; D051549:Glutathione S-Transferase pi; D005982:Glutathione Transferase; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D051759:Xeroderma Pigmentosum Group D Protein; C496556:GSTP1 protein, human; C071447:ERCC1 protein, human; C497292:ERCC2 protein, human
keywords: ERCC1; ERCC2; GSTM1; GSTP1; XRCC1; colorectal neoplasm; meta-analysis; oxaliplatin; pharmacogenetic